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Abstract 
Results from a small study into the efficacy of a Multi-Convergent Therapy intervention for patients with 
Chronic Fatigue Syndrome (CFS) had proved encouraging at the post-therapy and six-month follow-up time 
points. It was, however, important to re-evaluate these findings over a longer period. Eleven patients who had 
completed the original therapy trial responded to a follow-up call (91.7% response rate). Subjective data was 
returned by between 9 and 11 of the participants and 7 completed the objective measures. Participants in the 
current study completed a similar set of outcome measures as those used to assess treatment success previously. 
These data suggested that patients attending the therapy continued to show improvements in functioning, had 
lower levels of fatigue and disability, improved sleep quality and levels of activity and lower symptom scores at 
a three-year follow-up. The long-term efficacy for this treatment is suggested by these results. Multi-convergent 
therapy is indicated as a promising approach to the rehabilitation of CFS patients. 
 
Keywords: Chronic Fatigue Syndrome (CFS), Multi-convergent therapy (MCT), Long-term efficacy, Myalgic 
Encephalomyelitis (ME). 
 
 
1. Introduction 
 
1.1 Background 
Fatiguing illnesses are difficult to accurately assess and diagnose due to the symptom being largely subjective in 
nature.  Fatigue means different things to different people, and the term itself describes conditions ranging from 
moderate tiredness to clinical exhaustion (Thomas, 2018). 
 
The fatigue experienced in Chronic Fatigue Syndrome (CFS) is not only of sufficient severity to cause 
substantial functional impairment but it is also accompanied by four or more co-existing symptoms including 
those of a cognitive or neuropsychiatric nature (Fukuda et al., 1994).  The illness must be of at least six months 
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duration with the potential for it to become debilitating and persistent (Andersen, Permin & Albrecht, 2004).  
CFS has no known aetiology or distinctive biological diagnostic markers and appears to be more prevalent in 
middle-aged women who experience measurable cognitive impairment (Thomas & Smith, 2009) and high levels 
of somatic symptoms, anxiety, and depression (Thomas & Smith, 2006). Together with decreased personal, 
occupational and social activities which impact negatively on their quality of life, individuals with CFS are more 
likely to be unemployed than their peers (Smith, Thomas & Sadlier, 2009). Although the incidence of the 
syndrome is relatively low (Afari & Buchwald, 2003) this does not detract from the severe effect the illness has 
on the individual.  Decreased personal, occupational and social activities accompany the illness and combine to 
instil a sense of frustration and hopelessness within the patient.  In addition, financial concerns have been raised 
regarding the increased uptake of unemployment benefits, and the drain on healthcare resources brought about 
by the illness (Reyes et al., 1999; Reynolds, Vernon, Bouchery & Reeves, 2004).  For these reasons, the search 
to find a suitable treatment for this, often, debilitating illness became paramount.    
 
In a report by the Royal Colleges, practitioners were encouraged to provide a service for patients and take steps 
to manage patients in their care (Royal Colleges of Physicians, Psychiatrists & General Practitioners, 1996).  
Cognitive Behaviour Therapy (CBT) and graded exercise were recommended as the most successful methods for 
managing symptoms of the illness (CFS/ME Working Group, 2002). In their 2007 guidance, the National 
Institute for Health and Care Excellence (NICE) also regarded GET and activity management programmes and 
recommended that individualised, patient-centred programmes should also address sleep hygiene together with 
physical, emotional and cognitive symptoms (NICE, 2018).    
 
It was in response to the call for efficacy studies to manage the symptoms associated with CFS that we 
conducted a small randomised controlled trial of behaviour and graded exercise-based intervention in a multi-
convergent therapy (MCT) approach. MCT was developed by a registered NHS Physiotherapist who had 
recognised qualifications in all aspects of the therapy. The intervention was set up to provide a service for 
patients with a range of medically unexplained symptoms – such as irritable bowel syndrome and tinnitus – 
which did not respond to first-line medical intervention and where no solution was readily available (Sadlier & 
Stephens, 1995; Shaw et al., 1991).  
 
The commonality between these medically unexplained symptoms and CFS implied that MCT might be of value 
to patients with the syndrome.  Indeed, data collected retrospectively on the twenty-four patients completing a 
pilot study provided preliminary evidence as to the efficacy of the treatment for CFS (Sadlier, Evans, Phillips & 
Broad, 2000). 
 
MCT incorporates CBT and GET with other appropriate strategies in a holistic approach.  The CBT phase aimed 
to identify factors that can influence, precipitate or prolong the illness and improve sleep quality. Dysfunctional 
beliefs and thought patterns were explored and positive beliefs, thoughts, and behaviours re-enforced.  During 
the graded exercise phase, the therapist introduced a programme of planned activity and rest (referred to as 
‘pacing’) and explored the relationship between fatigue and cognition. The rationale for this aspect of the 
therapy was based upon a model suggested by Noakes and colleagues where gentle walking was introduced 
every second day at a level appropriate for each individual case to prevent post-exertional malaise (Noakes, St 
Clair Gibson & Lambert, 2005).  The distance and time walked were increased as the patient's confidence in the 
belief that this would not cause a relapse of their symptoms grew, and increases were controlled by the patient in 
discussion with the therapist. 
 
Mindfulness (or insight) meditation techniques were also blended with the CBT and graded exercise phases and 
patients were encouraged to fix their thoughts on the present without being distracted by the associations 
attached to those thoughts or sensations, such as fatigue or pain (Mason & Hargreaves, 2001; Carlson, Speca, 
Patel & Goodey, 2004; Grossman, Niemann, Schmidt & Walach, 2004; Kabat-Zinn, Lipworth & Burney, 1985).  
The therapy adopted a multi-dimensional approach which used aspects of behaviour modification, breathing and 
relaxation techniques, connective tissue massage and psychodynamic counselling. An in-depth description of our 
randomised controlled trial (RCT) is presented elsewhere (Thomas, Sadlier & Smith, 2006; Thomas, Sadlier & 
Smith, 2008). However, a brief overview of the trial is outlined below.   
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1.2 Previous Research 
In the original RCT (Thomas, Sadlier & Smith, 2006; Thomas, Sadlier & Smith, 2008), patients were recruited 
from a CFS Outpatient clinic by a single consulting physician.  Inclusion criteria for the trial were: (a) patients 
fitting the CDC criteria for CFS (Fukuda et al., 1994), (b) scores below 70% on the Karnofsky performance scale 
(Karnofsky, Abelmann, Craver & Burchenal, 1948) indicating significant functional impairment and (c) were 
willing to attend all therapy and assessment sessions.  Patients were excluded from the study if their fatigue was 
of known aetiology.   
 
Twelve patients were randomly allocated to the MCT group, 14 were allocated to a relaxation therapy group, and 
9 were allocated to a non-intervention control group.  Due to the small numbers in the study, patients recruited 
into the trial were assigned to a treatment group individually.  Referral letters for the MCT clinic, the relaxation 
therapist together with a letter indicating usual medical care were prepared for each patient who agreed to 
participate.  These were placed into a large blank envelope and one letter selected and posted by a colleague 
blind to the study's protocol.  The remaining letters were shredded.  The patient was contacted by the appropriate 
therapist, and subsequent assessment appointments were made through a third party. 
 
The relaxation therapy used in the trial was based on the Rapid Relaxation Technique of Lars-Goran Ost (Ost, 
1987).  This technique has been successfully used to alleviate a range of problems – such as tinnitus and pain – 
as well as CFS.  Rapid Relaxation offered the patient a way of coping with their symptoms and managing them. 
The therapist would guide the patient through the relaxation technique over a period of weeks, concentrating on 
different major muscle group each week.  We used this therapy as a comparison to MCT as relaxation therapy 
had been one of the approaches favoured by various centres and patient groups (Action for ME, for example) 
throughout England, Scotland and Wales and had been used as a comparison by other research groups (Deale, 
Chalder, Marks & Wessely, 1997).    
 
Individuals attended ten, 1-hour MCT or relaxation sessions per week for 10 weeks on a one-to-one basis.  The 
time spent on each component within MCT was decided during discussions between the therapist and the 
patient. 
 
Outcome measures for the trial included those assessing mood, performance and health-related measures that 
were developed previously (Thomas & Smith, 2009; Thomas & Smith, 2006).  In order to align our findings to 
other intervention studies, functional performance and global measures of health were also administered (Deale, 
Chalder, Marks & Wessely, 1997).  Data collection points included: (a) baseline (before randomisation), (b) 
immediately post-therapy and (c) 6-months post-therapy.  Control group data were collected to simulate a ten-
week therapy programme. To provide context to the current study, a brief overview of the RCT is presented 
here.   
 
At the post-therapy point, the MCT group reported significant improvements in alertness together with improved 
sleep quality and levels of activity than the relaxation and control groups.  They also reported significantly lower 
levels of anxiety and improvements in cognitive performance (e.g., motor speed and vigilance) than the control 
group.  A health-related measure of the number of physical and mental symptoms indicated that the MCT group 
reported significantly lower total symptom scores than the relaxation and control groups.   The global assessment 
of function measures suggested that the MCT group reported significantly greater improvements in their overall 
condition, lower levels of fatigue and a reduction in disability than the relaxation and control groups. 
 
Our findings also indicated that these improvements were maintained over a six-month period.  The MCT group 
continued to report significantly improved motor speed than the relaxation.  This group also continued to report: 
(a) higher levels of alertness, (b) lower levels of anxiety, (c) greater vigilance and (d) improved episodic memory 
than the control group.  Improvements in global measures of health were also reported at this time point 
including an overall improvement in their condition, lower fatigue levels and feeling far less impaired by their 
illness.   Regarding the primary outcome measure of the trial, attainment of a Karnofsky performance score of 
80% or more, the MCT group were significantly more likely to meet the desired outcome.  
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Although (as indicated above) the sample size for the study was small, a previous retrospective study suggested 
a recovery rate of 72% among those receiving MCT (Thomas, Sadlier & Smith, 2006) compared with 6% for 
untreated controls (Thomas & Smith, 2006).  These findings indicated that a sample of 8 MCT recipients and 8 
controls would have an 80% chance of detecting a treatment effect at the 5% level of statistical significance.  
Ethical approval for the therapy trial was granted by the Local Health Authority Ethics Committee and covered 
all aspects of the study up to the six-month follow-up data collection point. 
 
Findings from this small study suggested that MCT had the potential to effectively addressed a wide range of 
problems associated with CFS and improved patient outcomes which were sustained over a six-month period.  
However, whilst the success of our trial was of note, patients with CFS understand the illness is plagued with 
bouts of apparent recovery.  In these instances, the person can feel as if they have returned to normal health only 
to be struck down again with the illness weeks or even months later.  In terms of the longer-term efficacy of 
interventions for CFS, most trials report findings at 6-month follow-up (Nijhof, Bleijenberg, Uiterwaal, Kimpen 
& van de Putte, 2012) with a study by White et al (2013) conducting a follow-up assessment 1-year post-therapy 
(White, Goldsmith, Johnson, Chalder & Sharpe, 2013).  We judged it important to assess the efficacy of MCT 
over a longer period, that is 3-years after the final trial assessment, to see whether the intervention prevented 
relapses in the condition. 
 
2. Methods 
 
Ethical approval for the 3-year follow-up study was granted by the host institution’s departmental Research 
Ethics Committee. 
 
2.1 Participants 
The 12 CFS patients who completed the MCT arm of the original study were contacted by post and asked if they 
would attend a follow-up evaluation session. The relaxation and control groups were not contacted as, although 
they had been offered MCT following the outcome of the original study, they had not agreed to be contacted 
regarding further follow-up sessions. 
 
2.2 Procedure 
The MCT group were sent an information sheet describing the nature of the study along with a letter inviting 
them to participate in the follow-up study.  Data collection took place at the Research Unit, and the group 
completed the same outcome measures that were administered during the original trial.  Those who were not able 
to travel to the Unit completed the measures at home and returned them in a prepaid envelope. 
 
2.3 Primary Outcome Measure 
The main indicator for continued treatment success was the Karnofsky Performance Scale which categorises the 
patient according to their functional performance on a scale of 0 to 100% (Karnofsky et al., 1948).  The scale 
was modified, however, by removing the more catastrophic lower elements.  In this way, we were able to assess 
the ability of the patient to examine improvements in functioning subjectively.  
 
2.4 Secondary Outcome Measures 
2.4.1 Mood and performance (Thomas et al., 2006) 
The mood and performance test data were collected using a laptop computer which was connected to a simple 3-
button response box. The testing session lasted approximately fifteen minutes and recorded data regarding mood, 
memory, motor speed and vigilance. 
  
Mood: The task presented 18 visual analogue mood scales. Each scale composed of a pair of adjectives (e.g.) 
drowsy/alert or happy/sad.  Using the keys marked left or right on the response box, individuals asked to move 
the cursor on the screen towards the word they felt most represented their mood at that time.  The 18 scales were 
presented successively and scores between 1 and 51 recorded.  Using a factor analysis, three scores were derived 
from the 18 scales; alertness, hedonic tone, and anxiety. 
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Free Recall task objectively assessed episodic memory.  Individuals were shown a list of 20 words on the 
computer screen – each word was presented for two seconds.  Once all twenty words had been presented, the 
individual was asked to write down the words that they remembered – in any order.  They were given two 
minutes to complete this task.  The number of words remembered, the number of words correctly recalled, and 
the number of words incorrectly remembered were recorded.  
 
Variable Fore-Period Simple Reaction Time Task is an objective measure of motor speed.  During this task, an 
empty box was displayed in the centre of the screen.  At varying intervals (up to 18 seconds) a target square 
would appear inside the bigger box.  Individuals were asked to press a specified response key, using their 
dominant as soon as the saw the target square appear on the screen.  The task lasted for 3 minutes and data 
recorded included the reaction time for each presentation, the mean reaction time for each minute of the task and 
the number of trials completed per minute.  These data also provided a measure of overall mean reaction time 
and the total number of trials completed over the duration of the task.  
 
Repeated Digits Detection Task is a visual cognitive vigilance task which measures an individual’s ability to 
detect targets at irregular intervals.  The task successively presents 3-digit numbers in the centre of the screen at 
the rate of 100 per minute.  Usually, each 3-digit number differs from the one immediately preceding it (e.g., 
463, 563, 562).  Eight times per minute, however, the same 3-digit number is repeated on successive trials (e.g., 
463, 563, 563).  Individuals were asked to respond to the repeated numbers as quickly as possible by pressing 
the nominated key on the keyboard using the forefinger of their dominant hand.  The task lasted for 3 minutes 
and data recorded included the reaction time for each repeated digit recorded, the mean reaction time for each 
minute of the task.  The number of targets correctly identified, the number of false alarms and the number of 
missed targets were recorded per minute.  These data also provided a measure of overall mean reaction time and 
the total number of trials completed over the duration of the task.   
 
2.4.2 Global Measures of health (Deale et al., 1997) 
Ratings of overall improvement in illness condition and changes in the level of fatigue and disability were 
recorded on Likert-type scales.  Each scale ran from extreme negative through ‘no change’ to extreme positive 
responses.  Patients were asked to rate their responses in relation to their six-month follow-up scores.   
 
Quality of sleep and levels of activity were measured on Likert-type scales ranging from ‘much worse' through 
‘unchanged' to ‘much better' (in the case of sleep quality) and ‘significantly decreased' through ‘unchanged' to 
‘significantly increased' (for levels of activity).  A symptoms checklist with 28 physical (e.g., legs feeling heavy) 
and psychological ailments (e.g., anxiety/panic feelings) from which they could select the individual symptoms 
they were currently experiencing was also administered.  The number of positive responses was summed to 
provide total symptom score data (Thomas et al., 2006). 
 
2.5 Data Analysis 
Data for the current study included those variables which provided significant improvements previously 
(Thomas et al., 2006; 2008) continue in the longer-term.  Frequency data were used to compare the proportion of 
patients who continued to report normal function (70% and above and 80% or above) on the Karnofsky scale, 
activity levels and quality of sleep at 6-months and 3-years.  For the secondary outcome measures, negative 
scores were summed into a single variable as were the positive ones with the third variable being ‘no change.'  
Descriptive data were used to compare the performance data for the group at 6-months and 3-years.  Only those 
who competed for measures at both time points were included in the analysis.  
 
3. Results 
 
Of the twelve patients who have completed the original MCT trial, eleven completed at least part of the three-
year follow-up study (range=9-11) and seven completed the mood and performance measures. 
 
3.2 Primary Outcome Measure 
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Nine of the MCT group provided Karnofsky Performance score data group at the 3-year follow-up point. Seven 
respondents (77.8%) continued to report function scores of over 70%, indicating normal functioning, with 5 
recording scores of more than 80%.  
 
3.3 Secondary Outcome Measures 
3.3.1 Mood and performance 
Seven of the original MCT group completed the mood and performance tests.  Table 1 compares data from the 6-
month follow-up data from the original trial and the 3-year data. 
 
Table 1. Subjective ratings of mood and objective performance data for the MCT group at six months and three 
years.  Scores are means and s.d. 
 MCT patients (n=7) 
Measure Six-months 
post-therapy 
Three-years 
post-therapy 
Mood: 
Alertness 
Anxiety 
 
205.00 (59.45) 
76.00 (20.02) 
 
183.85 (33.56) 
71.43 (6.68) 
Episodic Memory: 
No. of words recalled 
 
10.00 (1.63) 
 
9.00 (1.82) 
Simple Reaction Time: 
Mean reaction time (msecs) 
 
394.25 (91.65) 
 
376.86 (109.70) 
Vigilance: 
Mean reaction time (msecs) 
No. of targets correct 
 
777.44 (90.31) 
15.57 (7.09) 
 
751.80 (106.33) 
16.28 (4.11) 
 
We can see in Table 1 that, although the small sample size precludes statistical analysis, the MCT patients 
appear to be maintaining the improvements in mood and performance recorded 6-months post-therapy 3-years 
later. 
 
3.3.2 Global measures of health 
Nine of the original MCT group completed the sleep measure, 10 completed the activity, fatigue, overall 
improvement in condition and disability measures and 11 completed the 28-item symptom checklist.  Table 2 
compares data from the 6-month follow-up data from the original trial and the 3-year data. 
 
Table 2. Three-year follow-up secondary health-related outcome measures for MCT patient group when 
compared to their six-month post-therapy scores.  Percentage scores indicate ‘better/much better' or ‘unchanged' 
from post-therapy or 6-month scores.  Scores are a percentage or mean and s.d. 
 
 MCT patient group 
Measure Six-months 
post-therapy 
Three-years 
post-therapy 
Improvement in condition (%) 100 90 
Fatigue (%) 67 90 
Lower levels of disability (%) 83 90 
Improved sleep (%) 83 90 
Improved activity (%) 100 91 
Total symptoms (mean) 11.58 (3.87) 11.54 (7.06) 
 
Only one person reported feeling worse at 3-year follow-up than they had at 6-month follow-up for each of the 
secondary outcome measures of their overall condition, fatigue, disability, sleep, and activity.  There was no 
difference between the mean total symptom scores at 6-months post-therapy and three-year follow-up. 
 
4. Discussion 
 
Chronic Fatigue Syndrome (CFS) is a condition which comes under the umbrella group of medically 
unexplained symptoms (MUS).  The severity of the fatigue experienced in the condition causes substantial 
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functional impairment, and it is also accompanied by four or more co-existing symptoms including cognitive 
deficits (Fukuda et al., 1994).   Individuals with CFS experience significant impairments in daily living and in 
social and occupational settings and spontaneous recovery rates from the illness are low (Thomas & Smith, 
2006). 
 
It was the increasing problem that MUS were presenting to both primary and secondary care that prompted the 
development of an outpatient clinic to provide a service for patients with these types of illnesses.  The 
subsequent intervention, multi-convergent therapy (MCT), had already shown to be of benefit to patients with 
irritable bowel syndrome and tinnitus as well as Chronic Fatigue Syndrome (Sadlier & Stephens, 1995; Shaw et 
al., 1991; Sadlier et al., 2000). 
 
MCT is a holistic, individualised programme which aims to address several symptoms associated with CFS 
including sleep, activity, and fatigue.  Poor sleep and reduced activity levels had been identified as confounding 
factors in perpetuating the illness.  The therapy combines aspects of Cognitive Behaviour Therapy (CBT) and 
Graded Exercise Therapy (GET) which previous studies had identified as the most consistently successful 
treatments for CFS (Deale et al., 1997; Sharpe et al., 1996; Fulcher & White, 1997).  In addition to these 
components, MCT included aspects of mindfulness meditation (Kabat-Zinn et al., 1985), relaxation techniques 
and psychodynamic counselling.  Heart rate monitors were also used to supervise the progress of exercise 
therapy. 
 
A small randomised controlled trial of the intervention was conducted where MCT was compared to relaxation 
therapy and a control group who received general medical care.  Overall the trial data provided evidence for the 
efficacy of the intervention across a range of impairments associated with CFS.  This included improved mood, 
fatigue, symptomology, sleep and activity levels following the 10-week therapy sessions.  We were also the first 
researchers to report objective evidence that intervention for CFS could improve cognitive performance (Thomas 
et al., 2006; 2008).  Whilst our findings were encouraging, and they only indicated the intervention's efficacy 
over a relatively short period of time – that is 6-months post-therapy.  Further assessment of the therapy over an 
extended period was warranted to assess the endurance of these positive outcomes as it was well established that 
periods of remission regularly occur in this condition (Reyes et al., 1999).  Previous behaviour therapy trials for 
CFS had, at most, collected follow-up data 12-months post-therapy (White et al., 2013). 
 
The stand-alone study described here reports data collected 3 years after the final assessment of the original trial.  
Eleven of the twelve CFS patients who attended MCT sessions in the original trial answered our three-year 
follow-up call (92% response rate).  Of these respondents, 78% reported that they were able to conduct the 
normal day-to-day activity with only a few signs or symptoms of the illness present on the Karnofsky scale 
(Karnofsky et al., 1948).  This scale was used in the original trial as both an inclusion/exclusion criterion and a 
primary outcome measure.  In terms of the secondary measures, the majority of those who had received MCT 
sessions reported that their overall condition maintained the improvement reported at the 6-month post-therapy 
level and that they continued to report lower levels of disability.  The significantly lower levels of fatigue and 
total symptom scores reported at 6-months post-therapy were also maintained at 3-year follow-up.  This is 
judged an important finding as fatigue, and the number of associated mental and physical symptoms are good 
indicators of recovery (submitted manuscript).    
 
We acknowledge that the sample size precluded any meaningful statistical analysis of the 3-year data.  However, 
our aim was to provide follow-up information on this group over an extended period.  In a much larger multi-
centre trial of CBT, GET, adaptive pacing therapy (APT) and specialised medical care (SMC). White et al. also 
used several standardised measures of fatigue and physical functioning (Chalder et al., 1993; Bowling, Bond, 
Jenkinson & Lamping, 1999) to define recovery (White et al., 2013).  In their study, recovery was interpreted as 
those patients who fell within the normal ranges for both scales.  Their study found that at the 52-week follow-
up point: (a) 30% of those receiving CBT, (b) 28% of those receiving GET, (c) 16% of those receiving APT and 
(d) 15% of those receiving SMC met the study criteria for recovery.  The authors concluded that although CBT 
or GET was more likely to facilitate recovery, only a small proportion of the patients did recover.  They 
attributed their findings to the heterogeneous nature of CFS and suggested that current therapies needed to be 
enhanced (White et al., 2013). It is judged that a holistic multi-convergent approach which addresses the 
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individual needs of the patient and that is patient centred offers the best way forward for sustainable 
improvement for patients with CFS.      
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